The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account (Q40748706)

23 September 2017

The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account (English)

1 reference

23 September 2017

Thomas Hünig

1

1 reference

PubMed ID

27191544

23 September 2017

language of work or name

English

0 references

publication date

18 May 2016

1 reference

23 September 2017

1 reference

23 September 2017

283

1 reference

23 September 2017

18

1 reference

23 September 2017

3325-3334

1 reference

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis

23 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Type 1 diabetes in BioBreeding rats is critically linked to an imbalance between Th17 and regulatory T cells and an altered TCR repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Crystal structure of a soluble CD28-Fab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Mitogenic signals through CD28 activate the protein kinase Ctheta-NF-kappaB pathway in primary peripheral T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

The effects of Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody in DSS-induced mice colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Regulatory T cells protect from local and systemic bone destruction in arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

In vivo activation of Treg cells with a CD28 superagonist prevents and ameliorates chronic destructive arthritis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

CD28 superagonist antibody treatment attenuated obliterative bronchiolitis in rat allo-orthotopic tracheal transplantation by preferentially expanding Foxp3-expressing regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Regulatory T cells ameliorate intrauterine growth retardation in a transgenic rat model for preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

TGN1412: scrutinizing preclinical trials of antibody-based medicines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Establishing risk of human experimentation with drugs: lessons from TGN1412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

21 January 2018

Lessons from TGN1412.

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Money and distorted ethical judgments about research: ethical assessment of the TeGenero TGN1412 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Cytokine release assays: current practices and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Toward experimental assessment of receptor occupancy: TGN1412 revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Clinical toxicity of interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

CD28 superagonist-induced regulatory T cell expansion ameliorates mesangioproliferative glomerulonephritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FFEBS.13754

21 January 2018

Identifiers

DOI

10.1111/FEBS.13754

1 reference

23 September 2017

1 reference

PubMed ID

27191544